Neurostimulation Devices Market by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others) Application (Pain Management, Hearing Loss, Urinary Incontinence, Parkinson's Disease, Epilepsy, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2027

ID: VPR/HC/235 Publishing Year: February 2021 Pages: 78 Format:   


The Smart Neurostimulation Devices Market size was valued at xx million in 2019 and is expected to reach xx million by 2027.

Neurostimulation is objective modulation of the Nervous Systems Activity. Neurological disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and cerebrovascular diseases influence on the central nervous system (CNS) and peripheral nervous system (PNS) of the human body. Neuromodulation is a process that makes use of an implantable medical device to modulate and alter neural activities for therapeutic purposes. Equipment that is used for Neuromodulation are called as Neurostimulators or Neurostimulation.

These devices are can be implanted or can be external. Neurostimulation Devices are directly established within the brain, PNS or CNS. Spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, and vagus nerve stimulators are some of the Neurostimulation devices used in treating patients with various diseases such as pain management, hearing loss, urinary incontinence, Parkinson's disease, and epilepsy. However, side effects such as allergic reaction and tingling or prickling of the skin due to implantation of neurostimulation device into the body and increase in cost of devices are expected to restrain the growth of the market. Furthermore, rising prevalence of Neurological disorders and lifestyle-related disorders, external funding for R&D, and demand for minimally invasive surgeries are other factors propelling the market growth. In addition, manufacturers are investing more R&D for the development of advanced products and technologies such as implantable Neurostimulation devices, which is expected to boost market growth of Neurostimulation Devices Market.

Segment Insight:

The Neurostimulation Devices Market is classified on the basis of device type, application, and region. Based on device type, the Neurostimulation Devices Market is divided into spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and others. On the basis of application, the market is classified into pain management, hearing loss, urinary incontinence, Parkinson's disease, epilepsy, and others.

By Device Type Insight:

Based on device type, the Neurostimulation Devices Market is divided into spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and others. Neurostimulation Device Implantation is a minimally invasive process and rising demand for such surgeries, due to shorter hospital stays and faster recovery.

By Application Insight:

On the basis of application, the market is classified into pain management, hearing loss, urinary incontinence, Parkinson's disease, epilepsy, and others. Some of the diseases encompassed under this segment include chronic pain, disk surgery pain, and leg pain. Epilepsy is a seizure causing neurological disorder and affects approximately 50 million people across the globe.

Major Key Players:

The report provides a comprehensive analysis of the key players operating in the Neurostimulation Devices Market, such as Abbott Laboratories, Aleva neurotherapeutics SA, Boston scientific corporation, ElectroCore Inc., EndoStim Inc., Medtronic plc, NeuroPace Inc., Nevro Corporation, Neuronetics Inc., NeuroSigma, Inc., and Synapse Biomedical Inc. Most of the key players in Neurostimulation Devices Market are focusing on business expansion to gain a higher revenue share through the adoption of strategies, such as mergers and acquisitions and new product development.

Key Market Segments:

By Device Type

  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Others

By Application

  • Pain Management
  • Hearing Loss
  • Urinary Incontinence
  • Parkinson's Disease
  • Epilepsy
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA


Frequently Asked Questions
Top companies such as, Aleva neurotherapeutics SA, Boston scientific corporation, ElectroCore Inc., EndoStim Inc., Medtronic plc, NeuroPace Inc., Nevro Corporation, Neuronetics Inc., NeuroSigma, Inc., and Synapse Biomedical Inc.

TABLE OF CONTENTS:

CHAPTER 1 MARKET INTRODUCTION

1.1. REPORT OVERVIEW

1.2. SCOPE OF THE STUDY

1.3. PRIMARY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

2.1. C-LEVEL EXECUTIVE’S OVERVIEW AND PERSPECTIVES

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. PRINCIPAL FINDINGS

3.2.1. Key investment pockets

3.2.2. Leading winning strategies

  3.2.3 Key Player Positioning

3.3. PORTERS FIVE FORCES OF COMPETITIVE ANALYSIS

 3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.4.4. Impact Analysis

3.5. IMPACT OF COVID-19 ON THIS MARKET

CHAPTER 4. NEUROSTIMULATION DEVICES MARKET, BY DEVICE TYPE

4.1. SYNOPSIS

4.1.1. Market size and forecast

4.2. SPINAL CORD STIMULATORS

4.2.1. Key market trends

4.2.2. Growth factors and opportunities

4.2.3. Market size and forecast

4.3. DEEP BRAIN STIMULATORS

4.3.1. Key market trends

4.3.2. Growth factors and opportunities

4.3.3. Market size and forecast

4.4. SACRAL NERVE STIMULATORS

4.4.1. Key market trends

4.4.2. Growth factors and opportunities

4.4.3. Market size and forecast

4.5. VAGUS NERVE STIMULATORS

4.5.1. Key market trends

4.5.2. Growth factors and opportunities

4.5.3. Market size and forecast

CHAPTER 5 NEUROSTIMULATION DEVICES MARKET, BY APPLICATION

5.1. SYNOPSIS

4.1.1. Market size and forecast

5.2. PAIN MANAGEMENT

   4.2.1. KEY MARKET TRENDS

4.2.2. Growth factors and opportunities

4.2.3. Market size and forecast

5.3. HEARING LOSS

4.3.1. Key market trends

4.3.2. Growth factors and opportunities

4.3.3. Market size and forecast

5.4. URINARY INCONTINENCE

4.4.1. Key market trends

4.4.2. Growth factors and opportunities

4.4.3. Market size and forecast

5.5. PARKINSON'S DISEASE

4.5.1. Key market trends

4.5.2. Growth factors and opportunities

  4.5.3. Market size and forecast

5.6. EPILEPSY

4.4.1. Key market trends

4.4.2. Growth factors and opportunities

4.4.3. Market size and forecast

CHAPTER 6 NEUROSTIMULATION DEVICES MARKET, BY REGION

6.1 SYNOPSIS

6.2 North America

6.2.1 Key market trends

6.2.2 Competitive scenario

6.2.3 Key growth factors and opportunities

6.2.4 Market size and forecast

6.3 Europe

6.3.1 Key market trends

6.3.2 Competitive scenario

6.3.3 Key growth factors and opportunities

6.3.4 Market size and forecast

6.4 Asia Pacific

6.4.1 Key market trends

6.4.2 Competitive scenario

6.4.3 Key growth factors and opportunities

6.4.4 Market size and forecast

6.5 LAMEA

6.5.1 Key market trends

6.5.2 Key growth factors and opportunities

6.5.3 Market size and forecast

CHAPTER 7 COMPANY PROFILES

  7.1. ABBOTT LABORATORIES

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Product portfolio

7.1.4. Business performance

7.1.5. Key strategic moves and developments

  7.2. ALEVA NEUROTHERAPEUTICS SA

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

7.3. BOSTON SCIENTIFIC CORPORATION

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product portfolio

7.3.5. Business performance

7.3.6. Key strategic moves and developments

7.4. ELECTROCORE INC.

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

7.4.6. Key strategic moves and developments

7.5. ENDOSTIM INC.

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product portfolio

7.5.5. Business performance

7.5.6. Key strategic moves and developments

7.6. MEDTRONIC PLC

7.6.1. Company overview

7.6.2. Company Snapshot

7.6.3. Operating business segments

7.6.4. Product portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

7.7. NEUROPACE INC.

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product portfolio

7.7.5. Business performance

7.7.6. Key strategic moves and developments

7.8. NEVRO CORPORATION

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

7.9. NEURONETICS INC.

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product portfolio

7.9.5. Business performance

7.9.6. Key strategic moves and developments

7.10. NEUROSIGMA, INC.

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Product portfolio

7.10.4. Key strategic moves and developments


PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]
PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]